Fokale Hyperhidrose

Rzany, Berthold; Müller, Christian P.; Hund, Martina

doi:10.1007/s00105-012-2331-1

Cited by 4 publications

(2 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 1 Typically, sweating in primary HH is bilaterally symmetrical and localized, and patients do not sweat during sleep. 2 , 3 The prevalence of primary HH has been reported to be 16·3% in Germany, 4·8% in the USA and 12·8% in Japan. 3 , 4 , 5 …”

mentioning

confidence: 99%

See 1 more Smart Citation

A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial*

et al. 2021

View full text Add to dashboard Cite

Summary Background Effective topical treatment options for patients with primary axillary hyperhidrosis (PAHH) are limited. A phase I trial showed promising results regarding the efficacy and safety of a topical cream containing glycopyrronium bromide (GPB). Objectives To assess the efficacy, safety and tolerability of a 4‐week topical treatment of GPB 1% cream in patients with PAHH vs. placebo. Methods In total, 171 patients (84 receiving placebo; 87 receiving GPB 1%) with PAHH were included in the 4‐week, multicentre, randomized, double‐blind, placebo‐controlled phase IIIa part of the pivotal study. Sweat production was measured by gravimetry. Patients rated the impact of disease with the Hyperhidrosis Disease Severity Scale (HDSS) and Hyperhidrosis Quality of Life Index (HidroQoL©). Results Absolute change in sweat production from baseline to day 29 in logarithmic values was significantly larger in the GPB 1% group compared with the placebo group (P = 0·004). The improvement in HidroQoL exceeded the minimal clinically important difference of 4. The proportion of responders was twofold higher for sweat reduction (–197·08 mg GPB 1% vs. –83·49 mg placebo), HDSS (23% GPB 1% vs. 12% placebo) and HidroQoL (60% GPB 1% vs. 26% placebo). Treatment was safe: most treatment‐emergent adverse effects were mild or moderate, and transient. Local tolerability was very good, with 9% of patients having only mild or moderate application‐site reactions. The most reported adverse drug reaction was dry mouth (16%), an expected anticholinergic effect of the treatment. Conclusions GPB 1% cream may provide an effective new treatment option exhibiting a good safety profile for patients with PAHH. The long‐term open‐label part (phase IIIb) is ongoing.

show abstract

mentioning

confidence: 99%

“…Eccrine sweat glands express various muscarinic acetylcholine (ACh) receptor subtypes and can therefore be activated by ACh and effectively blocked by muscarinic antagonists. 2 , 8 …”

mentioning

confidence: 99%

A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial*

et al. 2021

View full text Add to dashboard Cite

show abstract

Terapéutica láser de la hiperhidrosis axilar

Querol

Pastuschenko

2014

Piel

View full text Add to dashboard Cite

Topical anticholinergic medications for primary hyperhidrosis: A protocol for a systematic review and meta-analysis

Gao

Zhu

Liu

et al. 2022

Preprint

View full text Add to dashboard Cite

IntroductionPrimary hyperhidrosis (PHH) is a chronic condition characterized by excessive sweating. Several topical anticholinergic agents have been developed, but the evidence for the efficacy and tolerability of changing medication pathways of anticholinergics for PHH is limited.Methods and analysisPubMed, the Cochrane Library, Embase, the Web of Science, and the Cochrane Central Register of Controlled Trials will be searched from inception to March 2022 for studies that may be eligible for inclusion. Randomized controlled trials (RCTs) of PHH treated by topical anticholinergic drugs will be included. The primary outcomes include severity of hyperhidrosis measured quantitatively, the Hyperhidrosis Disease Severity Scale (HDSS) score or the proportion of subjects with a minimum 2-grade improvement from baseline in HDSS, the Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax) score and Dermatology Life Quality Index (DLQI). The secondary outcomes focused on safety and tolerability. Study selection, data extraction and assessment of risk of bias will be performed by two investigators independently. Data synthesis will be performed with RevMan 5.4 software.Ethics and disseminationEthical approval will not be needed in this review due to no data are involved in patient’s information and privacy. The results will be published and diffused in a peer-reviewed journal or relative conferences.Strengths and limitations of this studyThis systematic review will be the first to evaluate the efficacy and safety of topical anticholinergic agents in the treatment of PHH.Different inclusion criteria between studies and different skin sites where drugs applied may lead to clinical heterogeneity, which will be explored in the subgroup analysis.This study will also focus on evaluating systemic and topical safety and tolerability of topical application of anticholinergics.

show abstract

Fokale Hyperhidrose

Cited by 4 publications

References 25 publications

A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial*

A glycopyrronium bromide 1% cream for topical treatment of primary axillary hyperhidrosis: efficacy and safety results from a phase IIIa randomized controlled trial*

Terapéutica láser de la hiperhidrosis axilar

Topical anticholinergic medications for primary hyperhidrosis: A protocol for a systematic review and meta-analysis

Contact Info

Product

Resources

About